Significant bargain for willing opportunistic investorsSince Zemdri was approved and denied for complicated Urinary Tract Infections and Blood Stream Infections, respectively, shares of Achaogen have slipped considerably.
Even though Zemdri is only be approved for cUT, experienced physicians can still prescribe it off-label. That aside, Achaogen recently earned the CARB-X award, thereby giving credence to its meds.
I think this is a case of market overreaction and market manipulation.
I see Achaogen as an investment opportunity that suffered a temporary dramatic depreciation. It is now a significant bargain for willing opportunistic investors.
AKAO
AKAO Stock ReviewHello everyone! Today I have a short term chart analysis for AKAO. You can see the FULL video analysis by clicking the link below in my signature description!
I have new updated charts, and new video's every day. Please follow me on tradingview, and subscribe to me on youtube!
Leave any questions or comments below, and I will get back to you as soon as possible!
$AKAO Possible bottomSeverely oversold. Bears seem given up as price has hit original order block. Pirce target = $10. if break above triangle not sure, but $20 is possible.
Is AKAO time coming?Betting on good earnings. I see a strong upside potencial in the short/medium time frame.
Strong accumulation on 2016, Dec. and not too bad reaction to bad earnings on 2017 March.
